With no further treatment, the 1996 ten-month follow-up products data (n=92) from a high pollen period in Oregon, Washington and Idaho together showed a greater reduction for in the active group (n=43) than the placebo group (n=49) on the primary endpoint, high defined as a combination of symptom and rescue medication scores.8 Patients gave blood serum samples prior to the treatment in 1995 and one year later in 1996. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. blood and pressure Statistician Bradley products Rosebrook ran T-Tests comparing for average baseline high IgE levels to one-year. For the seasonal allergens reported, the active group (n=27) had on average a greater reduction in blood IgE than pressure the placebo group (n=34) for products 13 out for of 16 high and blood allergens.8

In January 1997, 62 subjects pressure who had been the placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent products a questionnaire for asking: How would you compare your overall high allergy (hay blood fever) symptoms pressure this spring to the last two springs? products 20 people responded, with 15 reporting for having high had the B12 treatment, and 5 not. blood 12 of the 15 reported at least a slight improvement in pressure overall products and for allergy symptoms, high and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 A blood bioequivalence study showed that a 3000 pressure mcg lozenge delivered products an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From the spring to the summer patients for with demonstrated allergic rhinitis received with the high cyanocobalamin (or placebo) containing blood lozenge twice daily for 21 consecutive days. All subjects also received C and B oral multivitamins for 21 days. Twice daily subjects maintained a nine-week diary on sneezing, pressure runny nose, nasal congestion, itchy products eyes, itchy nose and antihistamine (chlorpheniramine) for use. In the post-treatment period, high the active group (n=15) recorded on average a greater reduction in symptoms and blood in antihistamine use than the placebo group (n=9). The results yielded pressure and products reductions (0.1>p>0.01) in total weekly symptom/rescue for medication for the active group compared to high the placebo for weeks blood 2, 6, pressure 8 and 9. The results tend to replicate those of the studies on injectable cyanocobalamin.10